Patents by Inventor Carla A. Jaeger

Carla A. Jaeger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Engineered trimeric CD70 proteins and uses thereof
    Patent number: 12351618
    Abstract: Engineered trimeric CD70 proteins for use in ex vivo T cell manufacturing are described. Use of the proteins during manufacturing creates expanded T cell populations with enhanced properties such as earlier proliferation in culture; selective expansion of nave and memory T cell subsets; longer persistence in vivo following administration to a subject; and improved therapeutic effect. Use of the proteins as therapeutics provide anti-cancer and anti-viral effects. The proteins can also be used as agonistic cell culture reagents in in vitro uses.
    Type: Grant
    Filed: October 8, 2020
    Date of Patent: July 8, 2025
    Assignee: Fred Hutchinson Cancer Center
    Inventors: Carla A. Jaeger, Colin E. Correnti, Stanley R. Riddell
  • ENGINEERED TRIMERIC CD70 PROTEINS AND USES THEREOF
    Publication number: 20230174618
    Abstract: Engineered trimeric CD70 proteins for use in ex vivo T cell manufacturing are described. Use of the proteins during manufacturing creates expanded T cell populations with enhanced properties such as earlier proliferation in culture; selective expansion of nave and memory T cell subsets; longer persistence in vivo following administration to a subject; and improved therapeutic effect. Use of the proteins as therapeutics provide anti-cancer and anti-viral effects. The proteins can also be used as agonistic cell culture reagents in in vitro uses.
    Type: Application
    Filed: October 8, 2020
    Publication date: June 8, 2023
    Inventors: Carla A. Jaeger, Colin E. Correnti, Stanley R. Riddell